NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the third quarter of 2026.
MISSION Group (LSE:TMG) drew a bullish call from Stifel, which argued the marketing group's valuation overlooks a profit recovery driven by cost cuts and agency consolidation. The shares traded at 23.85p, up 4%, while the broker initiated coverage with a 'buy' rating and a 57p target, more than double the share price.
ST. LOUIS & LONDON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the appointments of Conor Daly and Jim Franz as Co-Heads of Leveraged Finance Sales in Europe, further strengthening the firm's global Fixed Income platform.
ST. LOUIS, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for July 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed.
Stifel reiterates Buy on Faron Pharmaceuticals after cash update secures runway to key trial readout
Stifel has reiterated its 'buy' rating on Faron Pharmaceuticals Limited (AIM:FARN), the Finnish biotech, maintaining a price target of €2.50 after the company's interims, which showed the company well-funded to push on with value-accretive work in the clinic. The stock closed at €0.48 on 25 August, implying upside of 418.1% to the target price.
ST. LOUIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that its Board of Directors has declared a cash dividend on shares of its common stock of $0.34 per share, payable September 15, 2026, to shareholders of record at the close of business on September 1, 2026.
Custom Health Holdings Inc (TSX:CHLT) just landed Buy-rated coverage from Stifel, with analysts setting a C$12 price target and pointing to upside as high as C$18 a share. The pitch: a pill-dispensing platform that's quietly solving one of healthcare's most expensive headaches.
